Status:
COMPLETED
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
Lead Sponsor:
Duke University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Atypical Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram ...
Detailed Description
Based on treatment outcome, longitudinal course, biologic and physiologic data, and family histories (Rabkin et al., 1996), the American Psychiatric Association's Diagnostic and Statistical Manual, Fo...
Eligibility Criteria
Inclusion
- age 18 to 65 years,
- DSM-IV episode of Major Depression non-psychotic with atypical features.
- ≥19 score on the 29-item HAM-D,
- ability to give informed consent, if patients are of child-bearing potential
- A minimum 2-week washout from existing psychotropics (5 weeks for fluoxetine).
Exclusion
- bipolar depression,
- Any Axis I psychotic disorder
- currently suicidal or suicide risk,
- history of substance abuse in the previous 12 months,
- history of hypersensitivity to escitalopram, or citalopram
- serious or unstable medical disorders,
- starting or terminating psychotherapy during the previous 12 weeks,
- ECT treatment in the previous 3 months,
- pregnancy or planning pregnancy.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00610506
Start Date
October 1 2005
End Date
May 1 2007
Last Update
May 31 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept Psychiatry, Duke University Medical Center
Durham, North Carolina, United States, 27705